The US Patent and Trademark Office has issued US Patent No. 9,572,774, titled “Dry Powder Vancomycin Compositions and Associated Methods,” to inhaled drug developer Savara, Inc., the company said.
In its statement, the company added, “This affords Savara important composition of matter protection for its AeroVanc program in the US, the largest market for the product, and is a key component of the company’s market protection strategy which also includes Orphan Drug and Qualified Infectious Disease Product protection.”
In addition, Savara said that the Canadian Intellectual Property Office has issued a notice of allowance for the company’s Canadian patent application, also titled “Dry Powder Vancomycin Compositions and Associated Methods.”
Both patents provide protection until at least 2032, and the company said that it is in the process of seeking patents for AeroVanc in other parts of the world.
In March 2016, Savara announced that it had raised $20 million to fund a Phase 3 study of AeroVanc for the treatment of MRSA lung infections in cystic fibrosis patients. At the time, the company said that it anticipated beginning the trial by the end of 2016; its web site now says that a Phase 3 trial is expected to be initiated in the second half of 2017.
Read the Savara press release.
